Precigen (NASDAQ:PGEN) Releases Earnings Results, Beats Expectations By $0.01 EPS

13 May 2026, 19:36 by Doug Wharley · The Cerbat Gem

Precigen (NASDAQ:PGEN – Get Free Report) posted its earnings results on Wednesday. The biotechnology company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.03) by $0.01, FiscalAI reports. The firm had revenue of $23.25 million for the quarter, compared to analyst estimates of $20.81 million. Precigen had a positive return on equity of 2,317.96% and a negative net margin of 2,588.21%.

Here are the key takeaways from Precigen’s conference call:

PAPZIMEOS delivered a strong first full quarter of sales, with Q1 2026 net product revenue of $21.6 million versus $3.4 million in Q4 2025, and management said momentum is continuing into Q2.
The company said launch adoption is broadening across major medical centers and community practices, with about 400 patients registered in the hub and roughly 25% coming from community settings.
Precigen highlighted strong access dynamics, citing more than 90% of insured lives covered in the U.S. and the recent permanent J-code as factors that should simplify claims and support broader uptake.
Financially, the quarter was better than the company’s prior launch phase, with operating loss of just $6 million and cash, cash equivalents and investments of $56.7 million; management reiterated it expects to reach cash flow break-even by the end of 2026 without needing to access capital markets.
Beyond the commercial launch, Precigen said it plans to start a pediatric PAPZIMEOS trial in Q4 2026, expects EMA review to continue, and will provide ASCO durability data next month along with additional PRGN-2009 updates later this year.

Precigen Trading Up 1.7%

Shares of Precigen stock traded up $0.07 during mid-day trading on Wednesday, hitting $4.15. 2,744,939 shares of the stock were exchanged, compared to its average volume of 4,198,495. Precigen has a twelve month low of $1.26 and a twelve month high of $5.47. The stock has a market capitalization of $1.48 billion, a price-to-earnings ratio of -3.10 and a beta of 1.07. The company has a 50-day simple moving average of $3.80 and a 200 day simple moving average of $4.07. The company has a current ratio of 3.09, a quick ratio of 2.83 and a debt-to-equity ratio of 4.46.

Insider Buying and Selling

In other Precigen news, Director Randal J. Kirk sold 4,772,781 shares of the business’s stock in a transaction on Monday, March 30th. The stock was sold at an average price of $3.30, for a total value of $15,750,177.30. Following the completion of the transaction, the director directly owned 302,213 shares in the company, valued at approximately $997,302.90. The trade was a 94.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 47.10% of the company’s stock.

Hedge Funds Weigh In On Precigen

Large investors have recently added to or reduced their stakes in the business. Xponance LLC boosted its position in shares of Precigen by 21.3% in the fourth quarter. Xponance LLC now owns 14,191 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 2,496 shares during the last quarter. BNP Paribas Financial Markets raised its stake in shares of Precigen by 6.1% during the third quarter. BNP Paribas Financial Markets now owns 51,796 shares of the biotechnology company’s stock valued at $170,000 after purchasing an additional 2,993 shares during the period. Intech Investment Management LLC lifted its stake in shares of Precigen by 5.2% in the fourth quarter. Intech Investment Management LLC now owns 63,018 shares of the biotechnology company’s stock worth $263,000 after acquiring an additional 3,137 shares in the last quarter. HighTower Advisors LLC raised its position in shares of Precigen by 4.2% in the 4th quarter. HighTower Advisors LLC now owns 104,560 shares of the biotechnology company’s stock valued at $437,000 after purchasing an additional 4,249 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in Precigen by 10.3% in the fourth quarter. The Manufacturers Life Insurance Company now owns 56,006 shares of the biotechnology company’s stock valued at $234,000 after acquiring an additional 5,222 shares in the last quarter. 33.51% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PGEN has been the topic of several recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Precigen in a report on Tuesday, April 21st. HC Wainwright increased their price target on shares of Precigen from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Wall Street Zen upgraded shares of Precigen from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Zacks Research upgraded shares of Precigen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Finally, Citizens Jmp increased their price target on shares of Precigen from $8.00 to $9.00 and gave the company a “market outperform” rating in a report on Thursday, March 26th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $9.50.

View Our Latest Analysis on Precigen

About Precigen

(Get Free Report)

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.